The Arterial Thrombosis drugs in development market research report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Arterial Thrombosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Arterial Thrombosis by 12 companies/universities/institutes. The top development phase for Arterial Thrombosis is preclinical with 11 drugs in that stage. The Arterial Thrombosis pipeline has ten drugs in development by companies and four by universities/ institutes. Some of the companies in the Arterial Thrombosis pipeline products market are: Oasis Pharmaceuticals, Jiangsu Hengrui Medicine and Virginia Commonwealth University.
The key targets in the Arterial Thrombosis pipeline products market include Coagulation Factor XI, Plasminogen Activator Inhibitor 1, and P2Y Purinoceptor 12.
The key mechanisms of action in the Arterial Thrombosis pipeline product include Coagulation Factor XI Inhibitor with three drugs in Phase I. The Arterial Thrombosis pipeline products include five routes of administration with the top ROA being Oral and six key molecule types in the Arterial Thrombosis pipeline products market including Small Molecule, and Synthetic Peptide.
Arterial Thrombosis overview
Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin, and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack, and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension, and high cholesterol level. Treatment includes thrombolytic agents and surgery.
For a complete picture of Arterial Thrombosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
